It's been a busy few months at Invenia Search, between the regular Biotech News Updates, company Spotlights, meeting clients, industry events and our recent rebrand and new website launch. Unlike the regular monthly news updates, funding is an occasional feature our Life Science Consultant Katie Davis puts together when time allows. And looking back at July–September, there was plenty worth sharing.
Q3 Themes
AI & computational biology: Significant investment in drug discovery, biological foundation models and protein engineering.
Life science tools: Funding across single-cell technologies, sequencing, computational microscopy and laboratory automation.
Diagnostics: Investment spanning liquid biopsy, molecular diagnostics, microbiome testing and precision oncology.
Therapeutics: Major financings across oncology, radiopharmaceuticals, genetic medicines and immune-mediated diseases.
September was particularly busy, with announcements ranging from early-stage Seed rounds and research grants to substantial late-stage financings and public offerings.
Single-Cell, Spatial & Multiomics
CellsBin® Inc. | Series A (undisclosed) → To scale its Rare-Cell Intelligence platform, combining microfluidics, imaging and single-cell profiling for cancer research and cell therapy monitoring.
Partillion Bioscience | $2.1M NIH SBIR grant → To expand Cell-Cell-seq, combining functional measurements of cell interactions with sequencing for immunology and cell biology research.
One Biosciences | €3.3M France 2030 funding → To advance OneMap, its AI-powered single-cell tumour profiling platform, towards clinical validation and regulatory approval for triple-negative breast cancer diagnostics.
Pixelgen Technologies | $15.5M Series B → To commercialise its Proxiome Kit for nanoscale mapping of cell-surface protein organisation and expand its software and product portfolio.
Yale School of Medicine | Nearly $25M ARIA grant → To investigate human brain development using single-cell multiomics, spatial analysis and organoid models, supporting research into autism.
Genomics, Sequencing & Transcriptomics
Primrose Bio | $2M NIH SBIR grant → To develop synthetic regulatory sequences that improve protein expression from DNA and RNA medicines using high-throughput screening and AI.
Aligned Bio | $3.6M financing → To commercialise its nanowire-based single-molecule detection platform for next-generation sequencing and ultrasensitive protein analysis.
Sampled | Up to $27.1M VA contract → To deliver long-read sequencing, DNA methylation profiling and proteomics for the Million Veteran Program under a five-year agreement.
Northwestern University | $30M NSF grant → To establish GENIE, investigating how 3D genome architecture regulates gene expression, cellular memory and regeneration.
Cincinnati Children's | $38.4M NHLBI grant renewal → To expand congenital heart disease genomics research, linking whole-genome sequencing with long-term clinical outcomes.
GeneMind Biosciences | Nearly RMB 600M Series D → To accelerate development and commercialisation of its genomic sequencing and multiomics technologies and support international expansion.
Proteomics, Cell Biology & Research Platforms
Pluristyx, Inc. | Undisclosed Series A initial close→ To expand its iPSC platform, supporting organoid manufacturing, cell engineering and cell therapy development.
Greenstone Biosciences | $1.2M Breakthrough T1D grant → To develop patient-derived pancreatic islet organoids and apply single-cell RNA sequencing and proteomics to study beta-cell vulnerability.
Utrecht University / Netherlands Proteomics Centre | €3.5M NWO grant → To upgrade proteomics infrastructure and integrate AI-based mass spectrometry analysis for disease research.
AcroCyte Therapeutics | Up to $4.3M ARPA-H award → To develop its R3CE platform for scalable expansion of kidney progenitor cells and organoids for regenerative medicine.
Ramona | $25M Series A → To scale its multi-camera computational microscopy platform for high-throughput live-cell imaging and AI-powered biomedical research.
Quantitative Biosciences Institute, UCSF | $46M ARIA grant → To map protein–protein interactions in autism, identifying how genetic mutations disrupt protein complexes and potential therapeutic targets.
Lab Automation, Sample Preparation & Biomanufacturing
BioHarvest Sciences | $1.4M innovation grant → To integrate AI, computer vision and high-throughput sensing into plant-cell culture for specialised biological compound production.
Everest Biolabs | $2.1M NIH SBIR grant → To develop automated, high-throughput extracellular vesicle isolation for plasma biomarker discovery and proteomics.
Codexis, Inc. | ~$23.1M net proceeds from public offering → To support its enzyme engineering technologies, including scalable oligonucleotide manufacturing, alongside research and commercial operations.
Dash Bio | $30M Series A → To expand its automated GLP bioanalysis platform, integrating robotics, laboratory software and molecular assays, and increase laboratory capacity.
AsymBio | ~$184M capital injection (RMB 1.24B) → To expand its automated GLP bioanalysis platform, integrating robotics, laboratory software and molecular assays, and increase laboratory capacity.
Cancer Screening & Liquid Biopsy
Children's Hospital of Philadelphia | $800K V Foundation grant → To investigate liquid biopsy screening for earlier cancer detection in children and young adults with Li-Fraumeni syndrome.
Respiro Diagnostics | £1M pre-seed → To develop breath-based liquid biopsy for lung cancer detection by analysing DNA, RNA and proteins in exhaled breath.
Intus Bio | $2.7M NIH/NCI award → To develop a microbiome-based colorectal cancer screening assay for earlier detection of cancer and precancerous lesions.
bioAffinity Technologies | $4M private placement → To support commercial operations for CyPath Lung, its non-invasive test for lung cancer risk assessment.
Senticell | Nearly $7M Seed + $400K NCI STTR grant → To advance red blood cell-based liquid biopsy for earlier cancer detection, including clinical studies in lung and pancreatic cancer.
Craif Inc. | ~$33M Series D → To advance clinical development of its urine-based microRNA cancer detection platform, including pancreatic cancer studies and regulatory preparation.
Freenome | ~$310.7M gross SPAC/PIPE proceeds → To scale its AI-enabled, multiomics blood-based cancer screening platform and commercial infrastructure following its Nasdaq listing.
Precision Oncology, MRD & Tumour Profiling
NHS Brain Cancer Genomic Network of Excellence | £2.1M funding → To expand rapid nanopore sequencing for brain tumour diagnosis, enabling faster molecular classification across NHS centres.
Pairidex | $4.9M Seed → To commercialise FusionMRD, its personalised RNA-based assay for monitoring measurable residual disease in fusion-driven blood cancers.
Prevision Medicine | $5.4M Seed → To commercialise its functional precision oncology platform, testing treatment responses in live patient-derived tumour cells.
Cerenome | Up to $20M financing facility → To expand CNSide, its cerebrospinal fluid-based molecular diagnostic for central nervous system cancers, through milestone-dependent royalty financing.
Women's Health & Microbiome Diagnostics
Juno Bio | $3.8M financing → To expand vaginal microbiome sequencing services and CLIA laboratory capabilities for reproductive and gynaecological health.
aitiologic | €6.4M Seed → To advance Aitios, its AI-enabled liquid biopsy platform combining cell-free DNA genomics, epigenomics and fragmentomics for preeclampsia risk assessment.
iPremom | €15M Seed → To validate and commercialise MaiRa, its first-trimester blood test for predicting pregnancy complications including preeclampsia.
Teal Health | $22M Series A → To expand access to its FDA-authorised Teal Wand for at-home HPV self-collection and cervical cancer screening.
Tiny Health | $33M Series B → To expand its gut and vaginal microbiome testing platform, clinical research and healthcare partnerships.
Evvy | $40M Series B → To expand vaginal microbiome testing, clinical research and personalised women's health applications using metagenomic sequencing.
Infectious Disease & Point-of-Care Diagnostics
Readily Diagnostics | ~$970K Gates Foundation grant → To develop affordable point-of-care molecular tests for sexually transmitted infections and antibiotic resistance markers.
Fuse Diagnostics | £1M financing → To commercialise Flip, its rapid molecular testing platform for pathogen and contaminant detection at the point of need.
Claryx | $3.5M pre-seed → To scale CloneLink, its pathogen genomic surveillance platform for tracking hospital-acquired infections and transmission chains.
En Carta Diagnostics | €5M financing (€3M equity + €2M non-dilutive) → To advance regulatory approval and commercialisation of point-of-need molecular tests for Lyme disease and sexually transmitted infections.
Zepto Life Technology | Up to $8.9M NIAID contract ($1.9M initially) → To develop its plasma cell-free DNA diagnostic for invasive fungal infections and support clinical validation.
Sapphiros | $12.4M BARDA award → To advance disposable molecular diagnostics for rapid biothreat pathogen detection outside centralised laboratories.
Vivid Dx | $15M Seed → To clinically validate its rapid diagnostic platform for bloodstream infections and antimicrobial resistance detection.
Neurological Biomarkers & Clinical Genomics
Constantiam Biosciences | $2.5M NIH SBIR Phase II award → To advance MAVEvidence, its functional genomics platform for interpreting genetic variants associated with Alzheimer's and related dementias.
Alzheimer's Drug Discovery Foundation & The Michael J. Fox Foundation for Parkinson's Research | $5M research partnership → To develop minimally invasive biomarkers for Alzheimer's and Parkinson's disease, including alpha-synuclein detection.
Population Genomic Screening Network | ~$8M NHGRI FY2026 funding → To evaluate primary-care genomic screening for hereditary cancers and familial hypercholesterolaemia across six research groups.
Lund University-led Consortium | $19.4M NIH grant → To validate an Alzheimer's blood test measuring MTBR-tau243 for disease staging, progression prediction and future regulatory approval.
University of Florida / 1Florida ADRC | $22M NIH grant → To expand Alzheimer's biomarker discovery, neuroimaging and longitudinal research through its university-led research centre.
Specialist Clinical & Immune Diagnostics
Retham Technologies | $1.5M financing → To commercialise HITDx, its blood-based diagnostic for detecting heparin-induced thrombocytopenia.
Biomerica, Inc. | ~$2.23M private placement agreed → To support operations and strategic development across its diagnostic testing business.
Virax Biolabs | $3.3M from warrant exercises → To support commercial activities across immune-response diagnostics and T-cell profiling technologies.
Trinity Biotech | $7M financing amendment ($2.5M new funding) → To support diagnostic and biosensor operations, including CGM+ development, with $4.5M of existing interest capitalised.
Bioinformatics, Multiomics & Biological Data
Biobase | Undisclosed pre-seed → To develop an AI-enabled platform connecting healthcare, laboratory and biobank research data with biotech and pharmaceutical organisations.
OmicsBank | $2.25M Seed → To expand its infrastructure linking genomic, pathology, imaging and clinical data for multiomics research and AI development.
Yale University | $3.1M NHGRI grant → To develop computational tools for interpreting mitochondrial DNA variants, improving genetic variant classification and clinical genomics.
Codebreaker Labs | $4.5M Seed → To scale functional genomics experiments and AI models for predicting and interpreting the effects of genetic variants.
Ambitious Bio | $6M Seed → To expand Corpus, its human tissue protein atlas, generating proteomic datasets for biological AI and drug target discovery.
AI Diagnostics, Clinical Imaging & Digital Pathology
Probably Genetic | Up to $9.9M ARPA-H contract → To develop multimodal AI for rare disease identification, integrating genomic, clinical and patient data to improve diagnostic pathways.
Aiforia Technologies | Up to €20M EIB venture debt facility → To develop and commercialise AI-powered digital pathology image analysis for clinical diagnostics and biomedical research.
Elucid | $55M Series D → To commercialise its AI-powered coronary CT imaging platform for quantifying atherosclerotic plaque and assessing cardiovascular risk.
AI Imaging, Predictive Analytics & Clinical Trials
Onco-Innovations Ltd. (CBOE: ONCO) / Redwood AI | DHIF research grant → To advance SynoGraph, combining causal AI and clinico-genomic data to predict oncology outcomes and support drug development.
Qureight | $20M Series B → To expand its 3D AI imaging platform, quantitative biomarkers and imaging CRO services for clinical trials.
Altis Labs | $25M Series A → To commercialise AI models that derive oncology trial endpoints and predict survival outcomes from radiology scans.
QuantHealth | $45M Series B → To scale its AI clinical trial simulation platform, helping pharmaceutical developers predict patient responses and optimise trial design.
AI Drug Discovery & Molecular Design
Sightera Biosciences | €3M pre-seed → To expand patient-data-driven AI drug discovery and advance its lead oncology molecular glue programme towards candidate selection.
Beyang Therapeutics | Nearly $30M Series A → To expand its ExCEED AI molecular design platform and advance oncology and ophthalmology drug programmes.
ProFound Therapeutics | Up to $35M Gates Foundation investment ($20M initially) → To apply its ProFoundry platform and agentic AI to discover novel proteins and therapeutic targets for preeclampsia.
Aureka Biotechnologies, Inc. | $100M Series B → To expand biological foundation models and its Lab-in-the-Loop platform, combining AI with high-throughput experimental validation.
Enveda | $311M Series E → To advance AI-discovered medicines through clinical development and scale PRISM, combining mass spectrometry, natural-product chemistry and automated experimentation.
Chai Discovery | $400M Series C → To develop its AI molecular design models, including Chai-3, for antibody engineering and drug discovery.
AI Protein Engineering, Antibodies & Genetic Medicines
Ride Therapeutics | Up to $7.3M Cystic Fibrosis Foundation investment → To develop AI-guided nanoparticle delivery technologies for genetic medicines targeting lung cells in cystic fibrosis.
Shennon Biotechnologies | $12M financing → To advance AI-enabled, single-cell functional screening for cancer target discovery and T-cell engager development.
Alchemab Therapeutics Ltd | £25M Series A extension → To expand its AI-powered Resiliome antibody discovery platform and advance its therapeutic pipeline.
BigHat Biosciences | $75M Series C → To scale its autonomous AI antibody engineering platform and advance AI-designed therapeutic candidates.
Basecamp Research | $140M Series C → To expand its EDEN biological AI models and advance AI-designed genetic medicines, including in vivo cell therapies.
Biological Foundation Models & Research Initiatives
Novo Nordisk Foundation × Broad Institute of MIT and Harvard | $53M research funding → To expand genomic, cellular and AI-driven research into obesity and type 2 diabetes.
AI BioDesign (by Allen Institute) | $95M research funding → To develop biological foundation models, research datasets and experimental tools through a collaborative AI biological design initiative.
—
